HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oxytrol OTC Success Depends On Driving Behavioral Changes

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck’s Oxytrol for Women could set the stage for other OTC switches indicated for chronic conditions, but the lifestyle changes recommended with the drug could be a hurdle. Oxytrol faces similar challenges to alli, another first-in-class switch with behavioral changes recommended.

You may also be interested in...

UK Looks To Switch Overactive Bladder Treatment

Maxwellia is seeking its second first-in-class switch in the UK with an application to reclassify from prescription-only to pharmacy status overactive bladder treatment Aquiette.

Merck’s Oxytrol Could Go From Rx Also-Ran To OTC Star – Analysts

Watson’s Oxytrol currently has just a 1% share of the overactive bladder drug market, but Kline and Kalorama analysts see sizable potential should it switch OTC.

Glaxo "Shakes Up" Alli Ad Strategy With New Agency

GlaxoSmithKline's decision to reassign the advertising contract for its alli OTC weight-loss drug two years after the product's launch could point to a fundamental problem with the brand's message, according to Steven Brozak, an investment banker working with biotech, medical device and health care firms


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts